drugset / Trial / NCT03722498
Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
Phase 2
Withdrawn
Sun Yat-sen University
Guangzhou No.12 People's Hospital · collabKaiping Central Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate safety and efficacy of combined hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin and sorafenib in hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization(TACE)
Timeline
- Start
- 2018-06-01
- Primary completion
- 2021-03-22
- Completion
- 2021-03-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leucovorin | Small molecule | — | Other |
| Subject | Oxaliplatin | Small molecule | — | Other |
| Comparator | Sorafenib | Small molecule | 400 mg | Oral |
| Subject | fluorouracil | Small molecule | — | Other |